immunology

Tharimmune (THAR) announced a $1.74 million registered direct offering consisting of common stock and warrants. Units are priced at $1.786, including one share or pre-funded warrant and a common warrant. President Street Global is the placement agent. Proceeds will fund working capital and general corporate purposes. The offering is expected to close around July 25, 2025. This funding aims to support Tharimmune’s work in immunology and inflammation therapies, including their clinical asset, TH104.

Apogee Therapeutics will announce pivotal 16-week data from its Phase 2 APEX trial for APG777, a novel inflation drug. The data, expected on July 7, 2025, could reveal differentiated efficacy and new dosing regimens for conditions like atopic dermatitis, asthma, and COPD. The company will host a conference call to discuss the findings.